Literature DB >> 33758868

Covid-19 in the California State Prison System: An Observational Study of Decarceration, Ongoing Risks, and Risk Factors.

Elizabeth T Chin1, Theresa Ryckman2, Lea Prince2, David Leidner3, Fernando Alarid-Escudero4, Jason R Andrews5, Joshua A Salomon2, David M Studdert2,6, Jeremy D Goldhaber-Fiebert2.   

Abstract

BACKGROUND: Correctional institutions nationwide are seeking to mitigate Covid-19-related risks.
OBJECTIVE: To quantify changes to California's prison population since the pandemic began and identify risk factors for Covid-19 infection.
DESIGN: We described residents' demographic characteristics, health status, Covid-19 risk scores, room occupancy, and labor participation. We used Cox proportional hazard models to estimate the association between rates of Covid-19 infection and room occupancy and out-of-room labor, respectively.
SETTING: California state prisons (March 1-October 10, 2020). PARTICIPANTS: Residents of California state prisons. MEASUREMENTS: Changes in the incarcerated population's size, composition, housing, and activities. For the risk factor analysis, the exposure variables were room type (cells vs dormitories) and labor participation (any room occupant participating in the prior 2 weeks) and the outcome variable was incident Covid-19 case rates.
RESULTS: The incarcerated population decreased 19.1% (119,401 to 96,623) during the study period.On October 10, 2020, 11.5% of residents were aged ≥60, 18.3% had high Covid-19 risk scores, 31.0% participated in out-of-room labor, and 14.8% lived in rooms with ≥10 occupants. Nearly 40% of residents with high Covid-19 risk scores lived in dormitories. In 9 prisons with major outbreaks (6,928 rooms; 21,750 residents), dormitory residents had higher infection rates than cell residents (adjusted hazard ratio [AHR], 2.51 95%CI, 2.25-2.80) and residents of rooms with labor participation had higher rates than residents of other rooms (AHR, 1.56; 95%CI, 1.39-1.74). LIMITATIONS: Inability to measure density of residents' living conditions or contact networks among residents and staff.
CONCLUSION: Despite reductions in room occupancy and mixing, California prisons still house many medically vulnerable residents in risky settings. Reducing risks further requires a combination of strategies, including rehousing, decarceration, and vaccination. FUNDING SOURCES: Horowitz Family Foundation; National Institute on Drug Abuse; National Science Foundation Graduate Research Fellowship; Open Society Foundations.

Entities:  

Year:  2021        PMID: 33758868      PMCID: PMC7987024          DOI: 10.1101/2021.03.04.21252942

Source DB:  PubMed          Journal:  medRxiv


  16 in total

1.  COVID-19, Decarceration, and the Role of Clinicians, Health Systems, and Payers: A Report From the National Academy of Sciences, Engineering, and Medicine.

Authors:  Emily A Wang; Bruce Western; Donald M Berwick
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

2.  Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons.

Authors:  Sachini Bandara; Alene Kennedy-Hendricks; Sydney Merritt; Colleen L Barry; Brendan Saloner
Journal:  J Addict Med       Date:  2020 Sep/Oct       Impact factor: 3.702

3.  Social Distancing and Incarceration: Policy and Management Strategies to Reduce COVID-19 Transmission and Promote Health Equity Through Decarceration.

Authors:  Brandy F Henry
Journal:  Health Educ Behav       Date:  2020-05-10

Review 4.  Medical Isolation and Solitary Confinement: Balancing Health and Humanity in US Jails and Prisons During COVID-19.

Authors:  David H Cloud; Cyrus Ahalt; Dallas Augustine; David Sears; Brie Williams
Journal:  J Gen Intern Med       Date:  2020-07-06       Impact factor: 5.128

5.  Epidemiology of COVID-19 Among Incarcerated Individuals and Staff in Massachusetts Jails and Prisons.

Authors:  Monik C Jiménez; Tori L Cowger; Lisa E Simon; Maya Behn; Nicole Cassarino; Mary T Bassett
Journal:  JAMA Netw Open       Date:  2020-08-03

6.  Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.

Authors:  Tarub S Mabud; Maria de Lourdes Delgado Alves; Albert I Ko; Sanjay Basu; Katharine S Walter; Ted Cohen; Barun Mathema; Caroline Colijn; Everton Lemos; Julio Croda; Jason R Andrews
Journal:  PLoS Med       Date:  2019-01-24       Impact factor: 11.069

7.  Risk Factors for SARS-CoV-2 in a Statewide Correctional System.

Authors:  Byron S Kennedy; Robert P Richeson; Amy J Houde
Journal:  N Engl J Med       Date:  2020-11-24       Impact factor: 91.245

8.  Mass Testing for SARS-CoV-2 in 16 Prisons and Jails - Six Jurisdictions, United States, April-May 2020.

Authors:  Liesl M Hagan; Samantha P Williams; Anne C Spaulding; Robin L Toblin; Jessica Figlenski; Jeanne Ocampo; Tara Ross; Heidi Bauer; Justine Hutchinson; Kimberley D Lucas; Matthew Zahn; Chun Chiang; Timothy Collins; Alexis Burakoff; Juli Bettridge; Ginger Stringer; Randolph Maul; Kristen Waters; Courtney Dewart; Jennifer Clayton; Sietske de Fijter; Radha Sadacharan; Linda Garcia; Naomi Lockett; Kirstin Short; Laxman Sunder; Senad Handanagic
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-08-21       Impact factor: 17.586

9.  A Retrospective Analysis and Comparison of Prisoners and Community-Based Patients with COVID-19 Requiring Intensive Care During the First Phase of the Pandemic in West Texas.

Authors:  Kiran Ali; Sanjana Rao; Gilbert Berdine; Victor Test; Kenneth Nugent
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

10.  Network Characteristics and Visualization of COVID-19 Outbreak in a Large Detention Facility in the United States - Cook County, Illinois, 2020.

Authors:  Uzay Kırbıyık; Alison M Binder; Isaac Ghinai; Chad Zawitz; Rebecca Levin; Usha Samala; Michelle Bryant Smith; Jane Gubser; Bridgette Jones; Kate Varela; Josh Rafinski; Anne Fitzgerald; Peter Orris; Alex Bahls; Sharon Welbel; Connie Mennella; Stephanie R Black; Paige A Armstrong
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-11-06       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.